[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser
M P
MP
Vyshinskaia
G V
GV
Min'kov
E D
ED
Nakhalova
T A
TA
Odzharova
A A
AA
Garin
A M
AM
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006321:Heart / Q000000981:diagnostic imaging / Q000187:drug effects*; D006333:Heart Failure / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000517:prevention & control*; D006801:Humans; D015635:Radionuclide Ventriculography; D011929:Razoxane / Q000627:therapeutic use*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D002317:Cardiovascular Agents; D011929:Razoxane; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil